We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $3B
1-Year Est. Return 46.72%
This Fund
S&P 500
This Quarter Est. Return
+4.66%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.98B
AUM Growth
–
Cap. Flow
+$1.68B
Cap. Flow %
56.29%
Top 10 Hldgs %
33.01%
Holding
88
New
63
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$82M
2
BIIB icon
Biogen
BIIB
+$71.3M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$71.3M
4
NTRA icon
Natera
NTRA
+$66.8M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$61.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 56.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DICE
26
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$26.2M 0.88%
+839,075
New +$27.4M
QDEL icon
27
QuidelOrtho
QDEL
$1.09B
$25.7M 0.86%
+300,437
New +$25.4M
GMED icon
28
Globus Medical
GMED
$10.4B
$25.5M 0.86%
+343,626
New +$23.4M
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.25B
$23.8M 0.8%
+1,493,121
New +$23.3M
ANAB icon
30
AnaptysBio
ANAB
$1.6B
$22.5M 0.75%
+726,122
New +$20.5M
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$22M 0.74%
+416,817
New +$20.3M
ESPR
32
DELISTED
Esperion Therapeutics
ESPR
$21.1M 0.71%
+3,393,405
New +$24.3M
APLS
33
DELISTED
Apellis Pharmaceuticals
APLS
$20.1M 0.68%
+389,596
New +$20.7M
RAPT
34
DELISTED
RAPT Therapeutics
RAPT
$19.8M 0.66%
+125,000
New +$20M
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$18.7M 0.63%
+413,600
New +$26.8M
TMDX icon
36
Transmedics
TMDX
$2.5B
$18.7M 0.63%
+303,185
New +$16.1M
ARGX icon
37
argenx
ARGX
$57.4B
$18.6M 0.62%
+49,200
New +$18.4M
DBVT
38
DBV Technologies
DBVT
$807M
$18.5M 0.62%
+1,210,779
New +$17.8M
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.66B
$18.2M 0.61%
+140,352
New +$16.3M
REPL icon
40
Replimune Group
REPL
$814M
$18M 0.6%
+662,349
New +$13.8M
STE icon
41
Steris
STE
$20.9B
$17.7M 0.59%
+95,694
New +$16.8M
EW icon
42
Edwards Lifesciences
EW
$47.6B
$17.6M 0.59%
+235,319
New +$18.1M
IMGN
43
DELISTED
Immunogen Inc
IMGN
$17.2M 0.58%
+3,474,497
New +$18.8M
COO icon
44
Cooper Companies
COO
$13.7B
$17.2M 0.58%
+208,460
New +$15.4M
ENTA icon
45
Enanta Pharmaceuticals
ENTA
$372M
$15.2M 0.51%
+325,838
New +$14.9M
LUNG icon
46
Pulmonx
LUNG
$49.4M
$13.7M 0.46%
+1,621,494
New +$15.4M
MRSN
47
DELISTED
Mersana Therapeutics
MRSN
$10.9M 0.37%
+74,508
New +$12.6M
IMTX icon
48
Immatics
IMTX
$1.24B
$10.9M 0.36%
+1,250,052
New +$12.9M
PTGX icon
49
Protagonist Therapeutics
PTGX
$8.75B
$10.1M 0.34%
+927,800
New +$7.83M
VRDN icon
50
Viridian Therapeutics
VRDN
$2.13B
$9.15M 0.31%
+313,403
New +$7.22M
1
2
3

Similar funds

NC
NZS Capital Denver, Colorado $3B AUM 21.29% 1-Year Est. Return
SGI
Swan Global Investments Durango, Colorado $3B AUM 15.66% 1-Year Est. Return
SP
SurgoCap Partners New York $2.99B AUM 39.34% 1-Year Est. Return
DIG
Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3B AUM 24.41% 1-Year Est. Return
ROTUOC
Regents of the University of California Oakland, California $3.01B AUM 11.91% 1-Year Est. Return
PHAM
Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Braidwell's Q4 2022 Portfolio in Review

Q4 2022 is the first quarter with a 13F filing on record for Braidwell, which disclosed 88 positions worth $2.98B. Its ten largest holdings account for 33% of the portfolio.

Its largest position is Glaukos: 1,661,851 shares worth $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets.

  • Braidwell's largest Q4 2022 buy was Glaukos: 1,661,851 shares worth $72.6M.
  • Braidwell's ten largest holdings make up 33% of its $2.98B portfolio in Q4 2022.
  • Braidwell disclosed 88 positions in Q4 2022, its first 13F filing on record.

Based on Braidwell's 13F filing for Q4 2022, filed 14 Feb 2023.